Alectinib (Alecensa) as monotherapy for first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)

Alectinib (Alecensa) as monotherapy for first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)
Country
Agency
Year work was carried out
Link
Details of use
Austria
GOeG
2018
Dissemination to decision-makers.
Austira
HVB
2018
LINK
National adaptation. Made minor changes to information used. Added budget impact or cost effectiveness analysis.
Austria
LBI-HTA
2018
LINK
1:1 in LBI-HTA Horison Scanning in Oncology-programme.
Croatia
AAZ
2018
LINK
National adaptation. Carried out translation. Added local information
Czech Republic
SUKL
2019
Used as background information.
Denmark
Danish Medicines Council
2018
LINK
Cited in report as background information.
Finland
HILA
2018
Read the report for background information. Were unable to fully utilize the report due to a different comparator. HILA also have to present our assessments in Finnish and in a specific structure.
Hungary
NIPN
2018
Used to justify our findings in the Technology Appraisal Committee meeting
Ireland
NCPE
2018-2019
Read the assessment for background information.
Italy
ASSR RER
2018
Dissemination through our website: alert of publication and link to document; summary and results reported on news page
Italy
UCSC
2018
National adaptation. Added local information.
Malta
MoH Malta DPA
2019
National adaptation. Read the assessment for background information. Added local information.
Norway
NOMA
2018
LINK
National adaptation. Added local information.
Poland
AOTMiT
2018-2019
National adaptation. Added local information.
Portugal
INFARMED
2018
National adaptation. Translated report. Added local information.
Slovakia
UNIBA
2018
National adaptation. Added local information.
Spain
AEMPS
2018
LINK
Cited in report as background or additional information.
Spain
OSTEBA
2018
LINK
PTJA03 assessment disseminated to oncologists and relevant decision makers (managers of the Pharmacy section of the Basque Health Service).
Spain
AETSA
2018
LINK
National adaptation. No changes to the information. Translated into Spanish. A summary of this assessment in Spanish together with the full English report has been published on AETSA’s website for dissemination. In addition, the report has been distributed to regional decision-makers and oncologists.
Sweden
TLV
2018
LINK
National adaptation. Added local information.
UK (England)
NICE
2018
LINK
Read the assessment for background information. Used the assessment to inform the evaluation or consideration of a company submission of evidence.
UK (Scotland)
SMC
2018
LINK
Used the assessment to inform the evaluation or consideration of a company submission of evidence. Updated evidence.
This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.